Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG. Wenzel C, et al. Among authors: pluschnig u. Cancer Chemother Pharmacol. 2002 Aug;50(2):155-9. doi: 10.1007/s00280-002-0476-9. Epub 2002 Jun 7. Cancer Chemother Pharmacol. 2002. PMID: 12172982 Clinical Trial.
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski CC, Lang A, Haid A, Jakesz R, Gnant M, Steger GG. Wenzel C, et al. Among authors: pluschnig u. Breast Cancer Res Treat. 2007 Jul;104(1):109-14. doi: 10.1007/s10549-006-9397-3. Epub 2006 Oct 24. Breast Cancer Res Treat. 2007. PMID: 17061042 Clinical Trial.
64 results